204 related articles for article (PubMed ID: 11556209)
1. [L-thyroxine therapy in differentiated thyroid carcinoma: criteria for evaluation of TSH suppression].
Kowalczyk P; Roskosz J; Jurecka-Tuleja B; Gubała E; Czernik E; Jarzab B
Wiad Lek; 2001; 54(5-6):268-76. PubMed ID: 11556209
[TBL] [Abstract][Full Text] [Related]
2. [Hormonal therapy in differentiated carcinoma of the thyroid gland].
Francia G; Davì MV; Petroziello A; Sussi PL
Chir Ital; 1994; 46(4):56-8. PubMed ID: 7882445
[TBL] [Abstract][Full Text] [Related]
3. The usefulness of a sensitive thyrotrophin assay in the fine adjustment of thyroxine therapy following ablation for carcinoma.
de Lange WE; Sluiter WJ; Doorenbos H
Neth J Med; 1989 Aug; 35(1-2):11-7. PubMed ID: 2779691
[TBL] [Abstract][Full Text] [Related]
4. [Treatment with L-thyroxine for differentiated thyroid carcinoma].
Łacka K
Wiad Lek; 2001; 54 Suppl 1():368-72. PubMed ID: 12182051
[TBL] [Abstract][Full Text] [Related]
5. Highly sensitive determination of TSH in the follow-up of TSH-suppressive therapy of patients with differentiated thyroid cancer.
Mann K; Saller B; Mehl U; Hörmann R; Moser E
Nuklearmedizin; 1988 Feb; 27(1):24-8. PubMed ID: 3368333
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
[TBL] [Abstract][Full Text] [Related]
7. Glucose tolerance and lipid profile in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomised controlled trial.
Heemstra KA; Smit JW; Eustatia-Rutten CF; Heijboer AC; Frölich M; Romijn JA; Corssmit EP
Clin Endocrinol (Oxf); 2006 Dec; 65(6):737-44. PubMed ID: 17121524
[TBL] [Abstract][Full Text] [Related]
8. Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma.
Diessl S; Holzberger B; Mäder U; Grelle I; Smit JW; Buck AK; Reiners C; Verburg FA
Clin Endocrinol (Oxf); 2012 Apr; 76(4):586-92. PubMed ID: 22059804
[TBL] [Abstract][Full Text] [Related]
9. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
Biondi B; Cooper DS
Thyroid; 2010 Feb; 20(2):135-46. PubMed ID: 20151821
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of TSH suppression using a 3d-generation TSH assay: diagnostic and therapeutic consequences].
Exer P; Staub JJ; Zulewski H; Müller B; Kunz M; Huber P
Schweiz Med Wochenschr; 1992 Dec; 122(51-52):1964-7. PubMed ID: 1475661
[TBL] [Abstract][Full Text] [Related]
11. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
[TBL] [Abstract][Full Text] [Related]
12. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial.
Eustatia-Rutten CF; Corssmit EP; Pereira AM; Frölich M; Bax JJ; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Mar; 64(3):284-91. PubMed ID: 16487438
[TBL] [Abstract][Full Text] [Related]
14. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer.
Montesano T; Durante C; Attard M; Crocetti U; Meringolo D; Bruno R; Tumino S; Rubello D; Al-Nahhas A; Colandrea M; Maranghi M; Travascio L; Ronga G; Torlontano M
Biomed Pharmacother; 2007 Sep; 61(8):468-71. PubMed ID: 17553654
[TBL] [Abstract][Full Text] [Related]
15. The role of thyrotropin suppression in patients with differentiated thyroid carcinoma.
Deasy J; Prichard RS; Evoy D; McDermott EW
Ir Med J; 2010; 103(7):202-5. PubMed ID: 20845598
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
17. Bone turnover markers in patients with differentiated thyroid carcinoma after levothyroxine withdrawal.
Gao YC; Gu Q; Liu QP; Ge WL; Lu HK
Clin Lab; 2010; 56(3-4):87-93. PubMed ID: 20476639
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
[TBL] [Abstract][Full Text] [Related]
19. [Hormone therapy as postoperative care in patients with differentiated thyroid cancer].
Kurihara H; Kuwahara T; Nakano Y
Nihon Geka Gakkai Zasshi; 1987 Oct; 88(10):1415-22. PubMed ID: 3696136
[TBL] [Abstract][Full Text] [Related]
20. Degree of thyrotropin suppression in differentiated thyroid cancer without recurrence or metastases.
Kamel N; Güllü S; Dağci Ilgin S; Corapçioğlu D; Tonyukuk Cesur V; Uysal AR; Başkal N; Erdoğan G
Thyroid; 1999 Dec; 9(12):1245-8. PubMed ID: 10646665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]